OncoMatch/Clinical Trials/NCT05065736
Using a PET Imaging Agent, 18F-Clofarabine (CFA), to Measure Deoxycytidine Kinase Activity in Metastatic Cancer
Is NCT05065736 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies 18F-Clofarabine for metastatic cancer.
Treatment: 18F-Clofarabine — The purpose of this study is to evaluate whether a new type of imaging study, called 18F-Clofarabine (CFA) PET/CT, can be used to image cancer pyrimidine metabolism in participants. PET (positron emission tomography) imaging is a way of looking at cancers that can reveal cancer metabolism. Presently, however, there are no imaging agents in routine use to look at an aspect of cancer metabolism (pyrimidine metabolism) that dictates whether certain cancer drugs, e.g., gemcitabine, are likely to be taken into the cancer cells. This clinical trial will be testing whether 18F-Clofarabine (CFA) could be an imaging agent to measure this aspect of cancer metabolism.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Lab requirements
Blood counts
anc >= 1500/ul; platelets >= 75,000/ul; hemoglobin >= 8.0 g/dl
Kidney function
serum creatinine <= 2.9 mg/dl
Liver function
ast/alt <= 2.5 x uln; total serum bilirubin <= 2.0 x uln
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Cleveland Clinic, Case Comprehensive Cancer Center · Cleveland, Ohio
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify